Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/19/2008

CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).

"REOLYSIN(R) is one of the more exciting targeted agents under development in oncology," said Dr. Frank Giles, Director of the Institute for Drug Development. "Our investigators within the CTRC at UTHSCSA are very excited to begin studying potential synergy with standard cytotoxic agents and are eager to expand our studies into other tumor types and utilizing other chemotherapy partner regimens."

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase 2 trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN(R), its pr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... -- Kalorama Information says that PCR is demonstrating its ... the United States and is the dominant ... the FDA,s Emergency Use Authorization (EUA) to authorize the emergency ... of the Ebola virus was an indication that the ... IVD industry and its biennial survey on diagnostics markets ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Danaher Corporation (NYSE:,DHR) announced that Executive Vice President ... presenting at the Robert W. Baird Industrial,Conference in ... 1:55 p.m. CST.,The audio will be simultaneously webcast ... a leading manufacturer of Professional,Instrumentation, Medical Technologies, Industrial ...
... ) reports third quarter 2008 results for the period,ended September 30, ... -- Sales increased 3.2% (-1.7% excluding foreign currency) compared to ... the quarter was up $1.7 million to $11.4 million ... of cash was $92.0 million at the end of third quarter ...
... Company,(Nasdaq: PRGO ; TASE) today announced that its ... share, payable on December 16, 2008 to,shareholders of record ... per share represents a ten percent increase over $0.05 ... Company is a leading global healthcare supplier that develops,manufactures ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:10/27/2014)... CA – October 28, 2014 – A new randomized ... proprietary blend of collagen and calcium, KoACT®, was far ... the leaching of calcium from bones and rebuilding new ... PubMed at: http://www.ncbi.nlm.nih.gov/pubmed/25314004 , ahead of print in ... The research was conducted by Bahram H. Arjmandi, PhD, ...
(Date:10/27/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market issues a ... Chief Technology Officer. Mr Tunnell examines the case for ... the variety of new payment solutions being released, consumers ... has its own attributes that promise to make payments ...
(Date:10/27/2014)... results from a safety and immunogenicity study, which ... that a live attenuated enterotoxigenic Escherichia coli ... a novel adjuvant, provided significant protection against disease. ... vaccine/adjuvant combination, which was 58.5 percent efficacious in ... highly rigorous ETEC human challenge model. The vaccine/adjuvant ...
Breaking Biology News(10 mins):New RCT: KoACT® beats calcium and vitamin D for optimal bone strength 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 3Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 4Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea 2
... The University of Manchester have made a surprising finding ... have big implications for research into human healing and ... salamanders have remarkable regenerative capacities, in contrast to mammals, ... tail a new one will regenerate within a week. ...
... Fujian and Shenzhen, China- An international research consortium, led ... completed the first genome sequence of the diamondback moth ... crops. This work provides wider insights into insect adaptation ... sustainable pest management. The latest study was published online ...
... release is available in French and German ... Royal Veterinary College London. Scientists have been able to ... the backbone of early tetrapods, the earliest four-legged animals. High-energy ... to reconstruct the backbones of the 360 million year old ...
Cached Biology News:The secrets of a tadpole's tail and the implications for human healing 2The secrets of a tadpole's tail and the implications for human healing 3The genome of diamondback moth provides new clues for sustainable pest management 2The genome of diamondback moth provides new clues for sustainable pest management 3Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 2Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 3
... The Vibratome Company has joined forces with ... the Vibratome 411301 Tissue Chopper. This tissue ... sections of tissue for metabolic experiments and ... irregular specimens available at biopsy or from ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... design, The Bioactive peptides are molecules of ... biological behaviour or activity which can be ... diagnostic, chemical and agro-food applications. In this ... peptides with superior properties for therapeutic applications. ...
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
Biology Products: